Double Ouch! 2 Monster Drops in 2 Trading Days

On Friday, I chastised Pfizer (NYSE: PFE  ) for not giving more information about the Food and Drug Administration's rejection of its abuse-deterrent pain drug, Remoxy. Perhaps investors in Pain Therapeutics (Nasdaq: PTIE  ) and DURECT (Nasdaq: DRRX  ) would have rather been kept in the dark.

Company

Price (Decline) June 24

Further Price (Decline) Today

Pain Therapeutics

(43%)

(35%)

DURECT

(31%)

(8%)

Source: Yahoo! Finance. Today's decline intraday.

The further decline today comes from Pain's disclosure of further details about the rejection. It turns out that my guess regarding a problem with the manufacturing section of the application was correct, but the possibility that this might be cleared up quickly went right out the window.

The FDA is concerned about inconsistencies between the manufacturing lots of Remoxy. Unfortunately, Pain Therapeutics and friends aren't sure whether it's a problem with the manufacturing directly or just the way they perform the tests on the drug to confirm it was produced correctly.

Given the unknowns about how to solve the problem, Pain Therapeutics doesn't see an approval happening in the next year, and it could take "significantly longer." With that kind of uncertainty, it's hard to recommend Pain Therapeutics as a bad-news buy.

Pfizer still has its recently approved Oxecta, an abuse-resistant pain drug using technology from Acura Pharmaceuticals (Nasdaq: ACUR  ) . But Oxecta is an immediate-release oxycodone, while Remoxy uses extended-release oxycodone for long-term pain sufferers. I'm not sure Acura will benefit from additional sales of Oxecta due to the lack of Remoxy on the market because Purdue Pharma has an approved abuse-deterrent extended-release oxycodone.

The best way to play this news might be to look at DURECT, which contributed its sustained-release technology to make Remoxy. The company has been beaten down but still has quite a few other projects, including phase 3 pain drug Posidur, which uses a different technology. DURECT and partners Hospira (NYSE: HSP  ) and Nycomed expect to have phase 3 data for Posidur available by the end of the year. Positive results would certainly help investors put the painful memory of Remoxy out of their minds.

If you're interested in keeping Pain, DURECT, and Acura on your watchlist, you can click on the green box next to their tickers to add them. Don't have My Watchlist account? Sign up here for free.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1512467, ~/Articles/ArticleHandler.aspx, 8/21/2014 7:12:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement